At Cadex Genomics, our mission and passion is to improve the lives of cancer patients. We develop novel, blood-based assays for patients with cancer. Over the past several years we have been working diligently to bring our first product to patients and the physicians who serve these patients. We are currently developing a new product called Alibrex, which is a blood-based assay that allows physicians to detect, in real-time, if the disease of their stage IV cancer patients is progressing. Alibrex is currently in development and will be available in 2023.
Under the current standard of care, it takes 3 months before an oncologist knows if a patient's treatment is working. Alibrex is a real-time therapy monitoring system that allows oncologists to assess whether a patient's treatment is working in just 12 days after starting treatment - regardless of tumor or therapy type. The benefits of Alibrex are:
The idea behind how Alibrex works is actually very simple. Tumors shed DNA into the blood. When tumors grow, the amount of DNA shed into the blood increases. The Alibrex system works by comparing the concentration of DNA in the blood prior to the start of treatments with the concentration of DNA in the blood after the administration of the 1st cycle of treatment. If the concentration of DNA in the blood increases, it is indicative of patient's tumor growing because the cancer treatment is ineffective, or the tumor is not responding to treatment.
The ability of Cadex Genomics' to detect extremely small changes in the quantity of DNA in the blood enables us to assess the treatment effectiveness after only 12 days from the first dose of therapy. Because the turn-around time of running our test is usually less than a day, we can usually get an answer back to the physician before the patient has been given a second cycle of therapy, in other words, in real time!
Stage IV Colorectal Cancer Patients (n = 39) versus Health Patients (n = 40)
This proof-of-concept study was conducted to determine if our technology was able to distinguish small fragments of DNA between cancer and non-cancer patients and between cancer patients who have been treated versus those who have not been treated. With an area under the curve (AUC) of 0.989, the results of this study were positive.
Dr. Scott Kopetz
Stage IV Colorectal Cancer Patients (n = 32)
This concordance study compared Alibrex results at 14 to 28 days against RECIST results at 9 to 12 weeks. A positive test outcome indicates the subject's disease progressed (PD), a negative test outcome indicates the subject's disease did not progress (non-PD). The results of this study were positive. Alibrex was able to predict 63% of subjects with PD or non-response to therapy. Most critically, there were no false-positive results.
Multi-site, Multi-country Study
Stage IV Colorectal, Breast & Lung Cancer Patients (n = 66)
This concordance study compared Alibrex results at 12 to 21 days against RECIST results at 9 to 12 weeks. A positive test outcome indicates the subject's disease progressed (PD) or non-response to therapy, a negative test outcome indicates the subject's disease has not progressed (non-PD), or responsive to therapy. The results of this study were positive. Alibrex was able to predict 60% of subjects with PD. Again, most critically, there were no false-positive results.
The CADEX-0001 results showed an AUC of 0.98 when Alibrex (at 12 to 21 days) is compared against RECIST3 (at 9 to 12 weeks).
CADEX-0001 ROC Curve3
Four factors distinguish the results of this study versus the MD Anderson:
The poster presentation included 20 patients. An additional 12 patients were added to the study in 2019. Sensitivity based on comparison to RECIST.
Results demonstrated a 60% sensitivity per RECIST. When we reclassify mixed-response subjects from PD to non-PD, the sensitivity increased to 80% (p-value <0.001). Mixed response patients are RECIST PD patients whose tumors did not grow but developed a new lesion. Physicians do not generally adjust treatment for mixed-response patients.
+1 (650) 292-2819
+1 (650) 446-5007
Send us your email address to receive updates on our latest news and events.